Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).
Volume: 12, Issue: 11_Supplement, Pages: C164 - C164
Published: Nov 1, 2013
Abstract
Clinical-stage ADCs with a maytansinoid cytotoxic moiety (AMCs) currently use either a cleavable, hindered disulfide linker or the non-cleavable, thioether linker, SMCC. Both types of linkers have demonstrated comparative advantages pre-clinically for different cancer targets. Pre-clinically, benefits of the thioether linker can include greater AMC tolerability, while benefits of a hindered disulfide linker can include enhanced AMC activity. A...
Paper Details
Title
Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).
Published Date
Nov 1, 2013
Volume
12
Issue
11_Supplement
Pages
C164 - C164
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History